Rose-tinted glasses might not save Genkyotex
Genkyotex has dredged the data to find a glimmer of hope with GKT831 in primary biliary cholangitis, but cash is running short.
EASL 2019 – Research reminds hep B bulls that progress will be slow
Presentations from Assembly Biosciences and Spring Bank Pharmaceuticals could disappoint those hoping to see more definitive steps towards a functional cure for hepatitis…
Déjà vu for Aveo and tivozanib
As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.
Akebia plays spot the difference with investors
Questions about Akebia's disclosure of liver toxicity in a trial raise a red flag over vadadustat, the company's experimental anaemia treatment.
Supernus struggles to gain attention
A phase III failure will do nothing to help Supernus’s SPN-812 compete against generic ADHD drugs.
Astrazeneca and Lexicon’s type 1 diabetes fortunes diverge, for now
Astrazeneca gets one over on Sanofi and Lexicon with European approval for Forxiga. US regulators might not be so forgiving.
The bubble bursts for Proteostasis
Investors had previously given Proteostasis the benefit of the doubt, but the company’s latest cystic fibrosis update leaves little hope to cling to.
No, aducanumab is not an Alzheimer’s drug either
Failure at a futility analysis blows a big hole in Biogen's pipeline. Can the company buy in growth or will its valuation sink enough for it to become a target?
Allergy’s lesson: don’t bet on studies that have been delayed
The long overdue readout of a pivotal birch pollen allergy vaccine trial draws a blank for the beleaguered UK company.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.